Tricyclic inhibitors of Hepatitis B virus

A compound of general formula (I):

• wherein:
• Cy is aryl or heteroaryl;
• X is O, NH, N—C1-6 alkyl, S, SO or SO2;
• Y, Y′, Y″ and Y′″ are each independently a single bond or C1-6alkanediyl optionally substituted with one or more R3;
• Z is CR4 or N;
• W is a single bond or NR5, wherein if W is a single bond, Z is N, and if W is NR5, Z is CR4;
• A is NR6, O, S or C1-6 alkanediyl optionally substituted with one or more R3;
• R1 is H or C1-6alkyl;
• R2 is selected from H, OH and C1-6alkyl;
• R3 is selected from H, OH, C1-6 alkyl, C3-8cycloalkyl and halogen or two geminal R3 form together with the atom to which they are attached a spiro-C3-8-cycloalkyl or a spiro-C3-8heterocycloalkyl or R3 is O forming together with the carbon atom to with it is bonded a C═O;
• R4 is H or C1-6alkyl;
• or when W is NR5 and Z is CR4, R2 and R4 may optionally form a C1-6alkanediyl bridge;
• R5 is selected from H, C1-6alkyl, C1-6alkylaryl, C1-6alkylheteroaryl and C1-6alkyl-C3-8cycloalkyl wherein each of said C1-6 alkyl, C1-6alkylaryl, C1-6alkylheteroaryl or C1-6-alkyl-C3-8cycloalkyl is optionally substituted with one or more substituents each independently selected from:
• OH, halogen, haloC1-6 alkyl, cyano and NH2;
• R6 is selected from:
• hydrogen;
• OH;
• C(O)R7;
• C(O)OR7;
• C(O)NHR7;
• C(O)N(R7)2;
• SO2R7;
• SO2NH(R7);
• SO2N(R7)2;
• C1-6 alkyl optionally substituted with one or more substituents each independently selected from the group consisting of:
• OH, halogen, CN, NH2, NH(R7), N(R7)2, aryl, heteroaryl, 3-7 membered saturated ring and 5-7 membered unsaturated ring, each of said saturated or unsaturated ring optionally containing one or more heteroatoms selected from the group consisting of 0, N and S and each of said aryl, heteroaryl, 3-7 membered saturated or 5-7 membered unsaturated ring being optionally substituted with one or more substituents each independently selected from OH, halogen, haloC1-6 alkyl, CN, haloC1-6alkoxy and C1-6alkoxy;
• aryl or heteroaryl ring, each of said aryl or heteroaryl ring being optionally substituted with one or more substituents each independently selected from:
• OH, halogen, haloC1-6 alkyl, CN, haloC1-6 alkoxy, C1-6 alkoxy, C1-6 alkyl, and NH2;
• and
• a 3-8 membered saturated or partially unsaturated cyclic or bicyclic ring optionally containing one or more heteroatoms each independently selected from the group consisting of:
• O, S and N, the 3-8 membered saturated or partially unsaturated cyclic or bicyclic ring being optionally substituted with one, two or more substituents each independently selected from the group consisting of:
• OH, halogen, CN, C1-6 alkyl, hydroxyC1-6alkyl, C(O)OR7, C(O)R7, haloC1-6 alkyl, haloC1-6alkoxy and C1-6alkoxy;
• R7 is selected from the group consisting of:
• C1-9alkyl, C3-8cycloalkyl, aryl, heteroaryl and 3-8 membered saturated or partially saturated heterocyclic ring, wherein each of said C1-9alkyl, C3-8cycloalkyl, aryl, heteroaryl or 3-8 membered saturated or partially saturated heterocyclic ring is optionally substituted with one or more substituents each independently selected from the group consisting of:
• OH, halogen, CN, C1-6alkyl, hydroxyC1-6alkyl, haloC1-6alkyl, haloC1-6alkoxy, C1-6alkoxy, NH2, OC(═O)C1-6alkyl, OP(═O)(OH)2, aryl, heteroaryl and NHC(═O)C1-6alkyl;
• Ra, Rb, Rc and Rd are each independently selected from the group consisting of:
• hydrogen, halogen, CN, C1-6alkyl, C1-6alkoxy, haloC1-6alkyl and haloC1-6alkoxy;
• and pharmaceutically acceptable salts, tautomers, stereoisomers thereof.